Literature DB >> 2171184

Failure of an in vitro lymphoproliferative assay specific for bovine herpes virus type 1 to detect immunised or latently infected animals.

G H Wentink1, V P Rutten, A C van Exsel, W A de Jong, H Vleugel, E J Hensen.   

Abstract

The in vitro lymphoproliferative assay specific for bovine herpes virus type 1 (BHV1) was tested for its ability to predict whether an animal was protected against challenge with virulent BHV1 and for its ability to identify animals latently infected with the virus. Three animals that had been in contact with a field strain of the virus, three that had been vaccinated with a modified live-virus vaccine seven weeks previously, six that had been vaccinated in the same way five months previously, and seven control animals that had had no previous contact with the virus were challenged with virulent BHV1. The 12 animals that had had previous contact with BHV1 all resisted the challenge well or fairly well, but six of them did not react positively in the in vitro lymphoproliferative assay. It was concluded that the assay did not give consistent evidence of the immune status of the animals. Four animals that had had previous contact with a field strain of BHV1 were treated with dexamethasone; they excreted BHV1 irrespective of whether they showed a positive response in the in vitro lymphoproliferative assay.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171184     DOI: 10.1080/01652176.1990.9694263

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  2 in total

Review 1.  BHV-1: new molecular approaches to control a common and widespread infection.

Authors:  L Turin; S Russo; G Poli
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

2.  Effects of bovine herpesvirus type 1 infection in calves with maternal antibodies on immune response and virus latency.

Authors:  M Lemaire; V Weynants; J Godfroid; F Schynts; G Meyer; J J Letesson; E Thiry
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.